Cardio-oncology Clinical Trial
Official title:
Prevention and Pharmacological Management of Cardiac Adverse Drug Reactions Induced by Drugs Used in Oncology. The PICARO Cohort
Recently, the medical management of cancer patients has considerably improved the prognosis
of these patients and today some cancers are becoming "chronic diseases". As a result, new
adverse effects (AEs) are observed, particularly cardiac.
These "new" cardiac AEs are the consequence of a significant increase in patients life
expectancy (delayed AEs not previously seen) but also the use of new pharmacological classes
of anticancer drugs such as kinase inhibitors. The incidence of these cardiac AEs varies
according to the patient profile and the anticancer molecules used, but their impact on the
morbidity and mortality of the patients is significant.
In this context, we started at the University Hospital of Caen Normandy in September 2017 a
cardio-oncology program entitled "prevention and pharmacological management of cardiac
adverse effects induced by drugs used in Oncology" (PICARO program). This program involves
the pharmacology department (opening of a dedicated consultation), the cardiology department
(opening of a dedicated ultrasound consultation), vascular medicine departement (opening of a
dedicated consultation) and the oncology federation. This program aims to be regional in the
future. We therefore propose to build a cohort backed up to the PICARO program to assess the
regional impact of cardiac AEs of anticancer drugs and thus to be better able to specify the
number of AEs, the incidence and regional prevalence of these drugs. .
The constitution of this cohort is only the first step towards the constitution in the near
future (2 years) of an observatory and then a regional registry of cardiac AEs induced by
anticancer drugs. The objectives associated with the establishment of such a registry would
be to reduce the number of cardiac AEs, the hospitalizations caused by these AEs, a better
information of health professionals and patients, an improvement in the screening of patients
at risk, all coming back in the context of health, clinical, epidemiological and
pharmacological surveillance.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT06309862 -
Immune Checkpoint Inhibitor Therapy for Cancer and Risk of Myocarditis or Cardiomyopathy
|
||
| Recruiting |
NCT06302634 -
Cardio-Oncology Rehabilitation Care Process
|
||
| Recruiting |
NCT05150080 -
Early Identification and Evaluation of Cyclophosphamide Cardiotoxicity
|